Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: Treatment outcomes in African-American children with ADHD

Journal of the National Medical Association

Volumn 97, Issue 10 SUPPL., 2005, Pages

  Starr, H Lynn ^a,b   Kemner, Jason ^a,b  

^a McNeil Consumer and Specialty Pharmaceuticals ^*

^b McNeil Laboratories Inc   (United States)

Author keywords

African Americans; Atomoxetine; Attention deficit disorder with hyperactivity; Methylphenidate

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; AFRICAN AMERICAN; APPETITE DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEAR; FEMALE; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PROPYLAMINES; TREATMENT OUTCOME;

EID: 26444448415     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. National Institutes of Health. Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. Available at: www.ncbi.nlm.nih.gov/books/bv. fcgi?rid=hstat4.section.19685. Accessed 01/26/05.
2. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S-49S.
3. Pelham WE, Gnagy EM, Chronis AM, et al. One-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural setting. Pediatrics. 2001;107:E105.
4. Wolraich ML, Greenhill L, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108:883-892.
5. Wilens T, Pelham W, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003;42:424-433.
6. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61:2391-2398.
7. Kratochvil CJ, Bohac D, Harrington M, et al. An open-label trial of atomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11:167-170.
8. Spencer T, Biederman J, Heiligenstein J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11:251-265.
9. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:e83.
10. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.
11. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
12. Spencer T, Heiligenstein JH, Biederman J, et al. Results from two proof-of concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63:1140-1147.
13. Kemner JE, Starr HL, Bowen DL, et al. Greater symptom improvement and response rates with OROS MPH versus atomoxetine in children with ADHD [abstract]. Int J Neuropsychopharmacology. 2004;7:S273-S274.
14. Faries DE, Yalcin I, Harder D, et al. Validation of the ADHD rating scale as a clinician administered and scored instrument. J Affen Disord. 2001;5:107-115.
15. Guy W. ECDEU Assessmenf Manual for Psychopharmacology. Rockville, MD: National Institutes of Health; 1976.
16. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
17. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Co.; 2005.
18. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.
19. Steinhoff KW, Wigal T, Swanson J. Single daily-dose ADHD medication treatment effect size evaluation. Poster presented at: 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry; October 14-19, 2003; Miami Beach, FL.
20. Faraone SV. Understanding the effect size of ADHD medications: implications for clinical care. Medscape. 2003;8:1-7.
21. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56:395-407.
22. MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1088-1096.
23. Arnold LE, Elliot M, Sachs L, et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consul Clin Psychol. 2003;71:713-727.
24. Samuel VJ, Biederman J, Faraone SV, et al. Clinical characteristics of attention deficit hyperactivity disorder in African American children. Am J Psychiatry. 1998;155:696-698.
25. Brown RT, Sexson SB. A controlled trial of methylphenidate in black adolescents. Attentional, behavioral and physiological effects. Clin Pediatr. 1988;27:74-81.